ID

12959

Descrição

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression; ODM derived from: https://clinicaltrials.gov/show/NCT00033514

Link

https://clinicaltrials.gov/show/NCT00033514

Palavras-chave

  1. 07/01/2016 07/01/2016 -
Transferido a

7 de janeiro de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Breast Cancer NCT00033514

Eligibility Breast Cancer NCT00033514

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
women aged > 18 years
Descrição

age, gender

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0079399
histologically documents metastatic breast cancer
Descrição

histology metastasis

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0019638
UMLS CUI [1,2]
C0027627
her2 positive using fish
Descrição

FISH her2 positive

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0162789
UMLS CUI [1,2]
C0242957
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
Descrição

previous treatment

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0087111
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
Descrição

measureable disease

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0475440
UMLS CUI [2]
C0860888
ecog performance status of 0 to 2
Descrição

ecog performance status

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1520224
a life expectancy of > 3 months
Descrição

life expectancy

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023671
use of effective means of contraception
Descrição

contraception

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
Descrição

chemotherapy, herceptin

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0338204

Similar models

Eligibility Breast Cancer NCT00033514

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
age, gender
Item
women aged > 18 years
boolean
C0001779 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
histology metastasis
Item
histologically documents metastatic breast cancer
boolean
C0019638 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
FISH her2 positive
Item
her2 positive using fish
boolean
C0162789 (UMLS CUI [1,1])
C0242957 (UMLS CUI [1,2])
previous treatment
Item
for phase i, patients who have previously received treatment for their metastatic disease are allowed to participate.
boolean
C0087111 (UMLS CUI [1])
measureable disease
Item
for the phase ii portion of the study, patients must have measureable disease (> 2 cm; > 1 cm on spiral ct scan)
boolean
C0475440 (UMLS CUI [1])
C0860888 (UMLS CUI [2])
ecog performance status
Item
ecog performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
a life expectancy of > 3 months
boolean
C0023671 (UMLS CUI [1])
contraception
Item
use of effective means of contraception
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
chemotherapy, herceptin
Item
for phase ii, prior cytotoxic chemotherapy and/or prior herceptin for their metastatic disease. prior treatment in the adjuvant setting is allowed.
boolean
C0392920 (UMLS CUI [1])
C0338204 (UMLS CUI [2])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial